Review



mic values against levofloxacin  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC mic values against levofloxacin
    In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of <t>MIC</t> values against <t>levofloxacin</t> of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC. *P < 0.05, compared with corresponding control
    Mic Values Against Levofloxacin, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 19319 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mic values against levofloxacin/product/ATCC
    Average 99 stars, based on 19319 article reviews
    mic values against levofloxacin - by Bioz Stars, 2026-02
    99/100 stars

    Images

    1) Product Images from "Quinic acid: a potential antibiofilm agent against clinical resistant Pseudomonas aeruginosa"

    Article Title: Quinic acid: a potential antibiofilm agent against clinical resistant Pseudomonas aeruginosa

    Journal: Chinese Medicine

    doi: 10.1186/s13020-021-00481-8

    In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of MIC values against levofloxacin of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC. *P < 0.05, compared with corresponding control
    Figure Legend Snippet: In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of MIC values against levofloxacin of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC. *P < 0.05, compared with corresponding control

    Techniques Used: In Vitro, Control

    Active antibiofilm compounds from metabolites of CA in LJF. a Antibiofilm activity of LJF and CA. b Growth curves of bacterial growth at different sub-MICs of CA. c GC–MS analysis of CA at 0.5, 1, 2, 4, 6, 24 h. The red arrow indicates the location of the peak of CA. d Measured ion spectrum (upper) and matched ion spectrum in NIST17 database (lower) of CA. e Metabolic pathways of CA in intestine (left) and liver (right). f In vitro antibiofilm effects of CA and its intestinal metabolites. g In vitro antibiofilm effects of CA and its liver metabolites. h GC–MS analysis of quinic acid at 0.5, 1, 2, 4, 6, 24 h. The red arrow indicates the location of the peak of quinic acid. i Measured ion spectrum (upper) and matched ion spectrum in NIST17 database (lower) of quinic acid. j The antibacterial activity ratio of caffeic acid and quinic acid to CA. k The antibacterial activity ratio of caffeic acid and its main metabolites to CA. l , m The antibacterial activity ratio of quinic acid and its major metabolites to CA. n – o Effects of dihydrocaffeic acid and gallic acid on the integrity (n) and the permeability (o) of bacteria membrane against MRSA. p - q Effects of dihydrocaffeic acid on the integrity ( p ) and the permeability ( q ) of bacteria membrane against MSSA. r Effects of quinic acid on EPS secretion in biofilm formation (upper) and in mature biofilm (lower). s – u The synergistic antibiofilm effects of sub-MIC quinic acid with levofloxacin ( s ), clarithromycin ( t ) and azithromycin ( v ). QA: quinic acid. *P < 0.05, **P < 0.01, compared with corresponding control
    Figure Legend Snippet: Active antibiofilm compounds from metabolites of CA in LJF. a Antibiofilm activity of LJF and CA. b Growth curves of bacterial growth at different sub-MICs of CA. c GC–MS analysis of CA at 0.5, 1, 2, 4, 6, 24 h. The red arrow indicates the location of the peak of CA. d Measured ion spectrum (upper) and matched ion spectrum in NIST17 database (lower) of CA. e Metabolic pathways of CA in intestine (left) and liver (right). f In vitro antibiofilm effects of CA and its intestinal metabolites. g In vitro antibiofilm effects of CA and its liver metabolites. h GC–MS analysis of quinic acid at 0.5, 1, 2, 4, 6, 24 h. The red arrow indicates the location of the peak of quinic acid. i Measured ion spectrum (upper) and matched ion spectrum in NIST17 database (lower) of quinic acid. j The antibacterial activity ratio of caffeic acid and quinic acid to CA. k The antibacterial activity ratio of caffeic acid and its main metabolites to CA. l , m The antibacterial activity ratio of quinic acid and its major metabolites to CA. n – o Effects of dihydrocaffeic acid and gallic acid on the integrity (n) and the permeability (o) of bacteria membrane against MRSA. p - q Effects of dihydrocaffeic acid on the integrity ( p ) and the permeability ( q ) of bacteria membrane against MSSA. r Effects of quinic acid on EPS secretion in biofilm formation (upper) and in mature biofilm (lower). s – u The synergistic antibiofilm effects of sub-MIC quinic acid with levofloxacin ( s ), clarithromycin ( t ) and azithromycin ( v ). QA: quinic acid. *P < 0.05, **P < 0.01, compared with corresponding control

    Techniques Used: Activity Assay, Gas Chromatography-Mass Spectrometry, In Vitro, Permeability, Bacteria, Membrane, Control



    Similar Products

    mic values against levofloxacin  (ATCC)
    99
    ATCC mic values against levofloxacin
    In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of <t>MIC</t> values against <t>levofloxacin</t> of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC. *P < 0.05, compared with corresponding control
    Mic Values Against Levofloxacin, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mic values against levofloxacin/product/ATCC
    Average 99 stars, based on 1 article reviews
    mic values against levofloxacin - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    mouse systemic infection organism challenge dose cfu mouse nemonoxacin levofloxacin p value mic nemonoxacin levofloxacin p value mic mg l ed50  (ATCC)
    99
    ATCC mouse systemic infection organism challenge dose cfu mouse nemonoxacin levofloxacin p value mic nemonoxacin levofloxacin p value mic mg l ed50
    In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of <t>MIC</t> values against <t>levofloxacin</t> of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC. *P < 0.05, compared with corresponding control
    Mouse Systemic Infection Organism Challenge Dose Cfu Mouse Nemonoxacin Levofloxacin P Value Mic Nemonoxacin Levofloxacin P Value Mic Mg L Ed50, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse systemic infection organism challenge dose cfu mouse nemonoxacin levofloxacin p value mic nemonoxacin levofloxacin p value mic mg l ed50/product/ATCC
    Average 99 stars, based on 1 article reviews
    mouse systemic infection organism challenge dose cfu mouse nemonoxacin levofloxacin p value mic nemonoxacin levofloxacin p value mic mg l ed50 - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    values for levofloxacin  (ATCC)
    90
    ATCC values for levofloxacin
    In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of <t>MIC</t> values against <t>levofloxacin</t> of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC. *P < 0.05, compared with corresponding control
    Values For Levofloxacin, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/values for levofloxacin/product/ATCC
    Average 90 stars, based on 1 article reviews
    values for levofloxacin - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of MIC values against levofloxacin of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC. *P < 0.05, compared with corresponding control

    Journal: Chinese Medicine

    Article Title: Quinic acid: a potential antibiofilm agent against clinical resistant Pseudomonas aeruginosa

    doi: 10.1186/s13020-021-00481-8

    Figure Lengend Snippet: In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of MIC values against levofloxacin of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC. *P < 0.05, compared with corresponding control

    Article Snippet: Fig. 1 In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of MIC values against levofloxacin of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC.

    Techniques: In Vitro, Control

    Active antibiofilm compounds from metabolites of CA in LJF. a Antibiofilm activity of LJF and CA. b Growth curves of bacterial growth at different sub-MICs of CA. c GC–MS analysis of CA at 0.5, 1, 2, 4, 6, 24 h. The red arrow indicates the location of the peak of CA. d Measured ion spectrum (upper) and matched ion spectrum in NIST17 database (lower) of CA. e Metabolic pathways of CA in intestine (left) and liver (right). f In vitro antibiofilm effects of CA and its intestinal metabolites. g In vitro antibiofilm effects of CA and its liver metabolites. h GC–MS analysis of quinic acid at 0.5, 1, 2, 4, 6, 24 h. The red arrow indicates the location of the peak of quinic acid. i Measured ion spectrum (upper) and matched ion spectrum in NIST17 database (lower) of quinic acid. j The antibacterial activity ratio of caffeic acid and quinic acid to CA. k The antibacterial activity ratio of caffeic acid and its main metabolites to CA. l , m The antibacterial activity ratio of quinic acid and its major metabolites to CA. n – o Effects of dihydrocaffeic acid and gallic acid on the integrity (n) and the permeability (o) of bacteria membrane against MRSA. p - q Effects of dihydrocaffeic acid on the integrity ( p ) and the permeability ( q ) of bacteria membrane against MSSA. r Effects of quinic acid on EPS secretion in biofilm formation (upper) and in mature biofilm (lower). s – u The synergistic antibiofilm effects of sub-MIC quinic acid with levofloxacin ( s ), clarithromycin ( t ) and azithromycin ( v ). QA: quinic acid. *P < 0.05, **P < 0.01, compared with corresponding control

    Journal: Chinese Medicine

    Article Title: Quinic acid: a potential antibiofilm agent against clinical resistant Pseudomonas aeruginosa

    doi: 10.1186/s13020-021-00481-8

    Figure Lengend Snippet: Active antibiofilm compounds from metabolites of CA in LJF. a Antibiofilm activity of LJF and CA. b Growth curves of bacterial growth at different sub-MICs of CA. c GC–MS analysis of CA at 0.5, 1, 2, 4, 6, 24 h. The red arrow indicates the location of the peak of CA. d Measured ion spectrum (upper) and matched ion spectrum in NIST17 database (lower) of CA. e Metabolic pathways of CA in intestine (left) and liver (right). f In vitro antibiofilm effects of CA and its intestinal metabolites. g In vitro antibiofilm effects of CA and its liver metabolites. h GC–MS analysis of quinic acid at 0.5, 1, 2, 4, 6, 24 h. The red arrow indicates the location of the peak of quinic acid. i Measured ion spectrum (upper) and matched ion spectrum in NIST17 database (lower) of quinic acid. j The antibacterial activity ratio of caffeic acid and quinic acid to CA. k The antibacterial activity ratio of caffeic acid and its main metabolites to CA. l , m The antibacterial activity ratio of quinic acid and its major metabolites to CA. n – o Effects of dihydrocaffeic acid and gallic acid on the integrity (n) and the permeability (o) of bacteria membrane against MRSA. p - q Effects of dihydrocaffeic acid on the integrity ( p ) and the permeability ( q ) of bacteria membrane against MSSA. r Effects of quinic acid on EPS secretion in biofilm formation (upper) and in mature biofilm (lower). s – u The synergistic antibiofilm effects of sub-MIC quinic acid with levofloxacin ( s ), clarithromycin ( t ) and azithromycin ( v ). QA: quinic acid. *P < 0.05, **P < 0.01, compared with corresponding control

    Article Snippet: Fig. 1 In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of MIC values against levofloxacin of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC.

    Techniques: Activity Assay, Gas Chromatography-Mass Spectrometry, In Vitro, Permeability, Bacteria, Membrane, Control